The altered expression of syndecan 4 in the uninvolved skin of venous leg ulcer patients may predispose to venous leg ulcer

Wound Repair and Regeneration

Volumn 16, Issue 4, 2008, Pages 495-502

  Nagy, Nikoletta ^a   Németh, István Balázs ^a   Szabad, Gábor ^a   Szolnoky, Gyõzõ ^a   Belsõ, Nóra ^a   Bata Csörgõ, Zsuzsanna ^a   Dobozy, Attila ^a   Kemény, Lajos ^a   Széll, Márta ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NEUROPILIN 1; SYNDECAN 4;

AGED; ARTICLE; CONTROLLED STUDY; DERMIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; HUMAN TISSUE; LEG ULCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ALLELES; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; HUMANS; IMMUNOENZYME TECHNIQUES; NEUROPILIN-1; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SKIN; SYNDECAN-4; VARICOSE ULCER; WOUND HEALING;

EID: 47349111276     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2008.00394.x     Document Type: Article

References (32)

1. Nagy N, Szolnoky G, Szabad G, Bata-Csörgö Z, Dobozy A, Kemeny M, Szell M. Single nucleotide polymorphisms of the fibroblast growth factor receptor 2 gene in patients with chronic venous insufficiency with leg ulcer. J Invest Dermatol 2005 124:1085 8.
2. Nagy N, Szolnoky G, Szabad G, Bata-Csörgö Z, Balogh A, Klausz G, Mandi Y, Dobozy A, Kemeny M, Szell M. Tumor necrosis factor-alpha -308 polymorphism and leg ulceration - possible association with obesity. J Invest Dermatol 2007 127:1768 9.
3. Wallace HJ, Vandongen YK, Stacey MC. Tumor necrosis factor-alpha gene polymorphism associated with increased susceptibility to venous leg ulceration. J Invest Dermatol 2006 126:921 5.
4. Herouy Y, May AE, Pornschlegel G, Stetter C, Grenz H, Preissner KT, Schöpf E, Norqauer J, Vanscheidt W. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol 1998 111:822 7.
5. Lauer G, Sollberg S, Cole M, Flamme I, Sturzebecher J, Mann K, Krieg T, Eming SA. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 2000 115:12 8.
6. Smith PD. Update on chronic-venous-insufficiency-induced inflammatory processes. Angiology 2001 1 (Suppl.):S35 42.
7. Kim BC, Kim HT, Park SH, Cha JS, Yufit T, Kim SJ, Falanqa V. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression. J Cell Physiol 2003 195:331 6.
8. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999 68:729 77.
9. Keum E, Kim Y, Kim J, Kwom S, Lim Y, Han I, Oh ES. Syndecan-4 regulates localization, activity and stability of protein kinase C-alpha. Biochem J 2004 378:1007 14.
10. Yoneda A, Couchman JR. Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biol 2003 22:25 33.
11. Kainulainen V, Wang H, Schick C, Bernfield M. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem 1998 273:11563 9.
12. Gallo R, Kim C, Kokenyesi R, Adzick NS, Bernfield M. Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. J Invest Dermatol 1996 107:676 83.
13. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez F, Detmar M, Goetinck P. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 2001 107:9 14.
14. Mundhenke C, Meyer K, Drew S, Friedl A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 2002 160:185 94.
15. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999 79:1283 316.
16. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, Klaqsburn M. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci USA 2000 97:2573 8.
17. Lundqvist K, Schmidtchen A. Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers. Br J Dermatol 2001 144:254 9.
18. Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F, Niwa H, Mijazaki JiJ, Hirota S, Kitamura Y, Kitsukawa T, Fujisawa H, Klagsbrun M, Hori M. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA 2002 99:3657 62.
19. Tordjman R, Lepelletier Y, Lemarchandel V, Cambot M, Gaulard P, Hermine O, Roméo PH. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002 3:477 82.
20. Kurschat P, Bielenberg D, Rossignol-Tallandier M, Stahl A, Klagsbrun M. Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration. J Biol Chem 2006 281:2721 9.
21. West DC, Rees CG, Duchesne L Patey SJ, Terry CJ, Turnbull JE, Delehedde M, Heegaard CW, Allain F, Vanpouille C, Ron D, Fernig DG. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem 2005 280:13457 64.
22. Zhang Y, Li J, Partovian C, Sellke FW, Simons M. Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. Am J Physiol Heart Circ Physiol 2003 284:2078 82.
23. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998 92:735 45.
24. Kojima T, Takagi A, Maeda M, Seqawa T, Simizu A, Yamamoto K, Matsushita T, Saito H. Plasma levels of syndecan-4 (ryudocan) are elevated in patients with acute myocardial infarction. Thromb Haemost 2001 85:793 9.
25. Branford White JC. The isolation of proteoheparan sulphate from sheep brain. Biochem Soc Trans 1977 5:1083 5.
26. Branford White JC. Proteoglycans in ovine brain. Experientia 1978 34:1036 7.
27. Branford White JC, Hudson M. Identifications of glycosaminoglycans in nerve terminals. J Neurochem 1977 28:581 8.
28. Morris JE, Ting YP. Comparison of proteoglycans extracted by saline and guanidinium chloride from cultured chick retinas. J Neurochem 1981 34:1594 602.
29. Woods A, Couchman JR. Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell 1994 5:183 92.
30. Chen C, Li M, Chai H, Yang H, Fisher WE, Yao Q. Roles of neuropilins in neuronal development, angiogenesis, and cancers. World J Surg 2005 29:271 5.
31. Maas-Szabowski N, Szabowski A, Stark HJ, Andrecht S, Kolbus A, Schorpp-Kistner M, Angel P, Fusenig ME. Organotypic cocultures with genetically modified mouse fibroblasts as a tool to dissect molecular mechanisms regulating keratinocyte growth and differentiation. J Invest Dermatol 2001 116:816 20.
32. Baraniak AP, Lasda EL, Wagner EJ, Garcia-Blanco MA. A stem structure in fibroblast growth factor receptor 2 transcripts mediates cell-type-specific splicing by approximating intronic control elements. Mol Cell Biol 2003 23:9327 37.